Teva Pharmaceutical Industries (TEVA) Debt to Equity (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Debt to Equity across 18 years of filings, most recently posting $2.02 for Q1 2026.

• Quarterly Debt to Equity fell 23.92% year-over-year to $2.02 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.02 (down 23.92% YoY) and the FY2025 annual result came in at $2.12, down 35.75% from the prior year.
• Debt to Equity declined to $2.02 in Q1 2026, from $2.12 in the prior quarter.
• Over five years, Debt to Equity peaked at $3.31 in Q4 2024 and troughed at $2.02 in Q1 2026.
• A 5-year average of $2.52 and a median of $2.47 in 2022 frame the typical range for Debt to Equity.
• Annual changes were most pronounced in 2024 — Debt to Equity jumped 35.43% — and 2025, when it slumped 35.75%.
• Tracing TEVA's Debt to Equity over 5 years: stood at $2.47 in 2022, then slipped by 1.07% to $2.44 in 2023, then soared by 35.43% to $3.31 in 2024, then sank by 35.75% to $2.12 in 2025, then decreased by 4.84% to $2.02 in 2026.
• Business Quant data shows TEVA's Debt to Equity at $2.02 in Q1 2026, $2.12 in Q4 2025, and $2.32 in Q3 2025.